Do pregnant patients receiving ferric carboxymaltose (FCM) develop hypophosphatemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Pregnant Patients and FCM-Associated Hypophosphatemia

Pregnant individuals receiving ferric carboxymaltose (FCM) do NOT appear to be at risk for hypophosphatemia, making them a unique exception to the well-documented hypophosphatemia risk seen in other patient populations. 1111

Key Evidence

The most recent and authoritative 2025 Lancet Haematology guidelines explicitly state: "Notably, pregnant individuals receiving this formulation do not appear to be at risk for hypophosphatemia." 1 This represents a critical distinction from the general population, where FCM causes hypophosphatemia in approximately 50-75% of patients receiving standard two-dose infusions.

Supporting Research Data

  • Prospective observational study (2024): Among 22 pregnant women treated with FCM, only 3 cases (13.6%) of maternal hypophosphatemia occurred, with just 1 case (4.5%) of neonatal hypophosphatemia. After adjustment for confounding factors, IV iron administration had no impact on cord blood phosphate levels (p=0.919). 2

  • Controlled study (2018): In pregnant subjects receiving 1g FCM, serum phosphate reached its nadir at Day 7 but recovered by Day 21—significantly faster than in CKD patients (Day 42) or controls. 3

Clinical Context and Mechanism

Why Pregnancy is Protective

While the exact mechanism remains unclear, pregnancy appears to confer protection against FCM-induced hypophosphatemia despite the drug's well-established effect on fibroblast growth factor 23 (FGF23) and urinary phosphate excretion in non-pregnant populations. This may relate to:

  • Altered phosphate homeostasis during pregnancy
  • Increased intestinal phosphate absorption
  • Hormonal influences on renal phosphate handling

Contrast with General Population

In non-pregnant adults, FCM consistently causes:

  • Hypophosphatemia rates of 50-75% 11
  • Severe hypophosphatemia (<1.0 mg/dL) in some cases 1
  • Persistent hypophosphatemia lasting weeks to months 14
  • Potential complications including osteomalacia and pseudofractures with repeated dosing 14

Practical Implications

For pregnant patients with iron deficiency anemia:

  • FCM can be used safely without routine phosphate monitoring 1
  • The 2025 guidelines recommend IV iron (where acceptable) in the second trimester and suggest offering it over oral iron in the third trimester 11
  • Single infusion provides rapid iron repletion with improved hemoglobin response compared to oral iron 56

Important caveats:

  • This protection applies specifically to pregnancy; postpartum patients should be considered at standard risk
  • The FDA label notes that severe hypersensitivity reactions can cause fetal bradycardia, particularly in second and third trimesters 77
  • While hypophosphatemia risk is minimal, standard monitoring for other adverse events remains appropriate

When to Reconsider FCM

For patients requiring repeated courses of IV iron (even in pregnancy), consider alternative formulations like ferric derisomaltose, which shows significantly lower hypophosphatemia rates (3.9% vs 47% with FCM) in general populations. 48 However, the pregnancy-specific data suggests this concern is less relevant during gestation itself.

References

Research

Newborn phosphocalcic metabolism after intravenous iron administration during pregnancy.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2024

Research

A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2018

Related Questions

Which intravenous iron formulations are recommended for patients needing repeated infusions, and how do ferric derisomaltose (iron isomaltoside) and iron sucrose compare regarding dosing schedule, safety, and risk of hypophosphatemia?
In an adult post‑gastric bypass patient with mild iron‑deficiency anemia (hemoglobin 10.1 g/dL) who received a single intravenous iron infusion yesterday and now reports four days of dizziness, what is the appropriate evaluation and management?
Are certain individuals more prone to developing severe prolonged hypophosphatemia after ferric carboxymaltose (Ferinject) infusion?
Can Venofer (iron sucrose) be used for iron repletion in patients who have developed or are at risk for hypophosphatemia after an iron infusion?
For a patient with mildly elevated alkaline phosphatase before ferric carboxymaltose infusion, which iron formulation should be used and how should phosphate be monitored to prevent hypophosphatemia?
What imaging studies can be used to rule out stroke in a patient who cannot undergo MRI because of titanium spinal hardware?
Which intravenous iron formulations are recommended for patients needing repeated infusions, and how do ferric derisomaltose (iron isomaltoside) and iron sucrose compare regarding dosing schedule, safety, and risk of hypophosphatemia?
Is mirogabalin appropriate for treating abdominal pain?
What are the diagnostic criteria for acute kidney injury?
Why is it necessary to monitor serum chloride, calcium, sodium, potassium, magnesium, and phosphate in a patient with metastatic lung cancer receiving pemetrexed (700 mg) and carboplatin (500 mg) chemotherapy?
What is the clinical significance of lip puckering when assessing the orbicularis oris (O‑R‑B‑I‑C) muscle?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.